• Notable additional benefit observed with an added reduction in MADRS1 score leading to an average 13-point reduction from baseline at Week 52 with durability extended out to 1 year for participants who were randomized to the 25 mg arm and received an additional dose
  • For participants randomized to Placebo arm who received first dose of COMP360 25 mg in open-label Part C, data further reinforces that a single 25 mg dose can produce rapid onset, meaningful effect and durability
  • For all participants in Part C who received a 25 mg open-label dose, strong response and remission rates were observed with 40%-45% responders2 and approximately 30% remitters3 across all timepoints 6 weeks post the Part C dose
  • This 1-year data further supports the belief that, if approved, COMP360 could establish a new standard of care in TRD that can be life-changing for patients − moving beyond daily or frequent administration toward an option that could provide durable benefit with just a few treatments a year
  • COMP360 safety profile in Part C is consistent with Parts A and B. COMP360 continues to demonstrate a generally well-tolerated and safe profile with no new safety findings
  • Rolling NDA submission and review underway and final submission on track to be completed in Q4
  • Continue to expect commercial launch in first half of 2027